<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620162</url>
  </required_header>
  <id_info>
    <org_study_id>V114-027</org_study_id>
    <secondary_id>V114-027</secondary_id>
    <secondary_id>2018-001151-12</secondary_id>
    <nct_id>NCT03620162</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the safety, tolerability, and immunogenicity of the&#xD;
      Pneumococcal Conjugate Vaccines (PCVs) V114 and Prevnar 13™ in healthy infants switched from&#xD;
      Prevnar 13™ to V114 during the four-dose PCV immunization schedule.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Actual">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Injection-site Adverse Event (AE)</measure>
    <time_frame>Up to ~14 days after each vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, the percentage of participants with solicited injection-site AEs was assessed for up to ~14 days after each vaccination. The solicited injection-site AEs assessed were erythema/redness, induration/hard lump, tenderness/pain and swelling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Solicited Systemic AE</measure>
    <time_frame>Up to ~14 days after each vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, the percentage of participants with solicited systemic AEs was assessed for up to ~14 days after each vaccination. The solicited systemic AEs assessed were appetite lost/decreased appetite, irritability, drowsiness/somnolence and hives or welts/urticaria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)</measure>
    <time_frame>Up to ~6 months after Vaccination 4 (up to ~19 months)</time_frame>
    <description>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgement. Relatedness of an SAE to the study vaccine was determined by the investigator. Per protocol, the percentage of participants with vaccine-related SAEs was assessed through 6 months following Vaccination 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Anti-Pneumococcal Polysaccharide (PnP) Immunoglobulin G (IgG) For 13 Shared Serotypes Contained in V114 and Prevnar 13™ at 30 Days Post Vaccination 4</measure>
    <time_frame>30 Days after Vaccination 4 (Months 11-14)</time_frame>
    <description>The GMC of anti-PnP serotype-specific IgG for 13 shared serotypes contained in V114 and Prevnar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) was assessed using a pneumococcal electrochemiluminescence (PnECL) assay. Per protocol, 13 IgG serotypes in Groups 2, 3, 4 (experimental arms) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4 as a pre-specified primary outcome analysis; 13 IgG serotypes in Group 5 (experimental arm) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4, as a separate protocol-specified secondary outcome analysis and reported later in the record.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Group 5 Versus Group 1 + Group 2: Percentage of Participants With Anti-Hepatitis B Surface Antigen (HBsAg) ≥10 mIU/mL at 30 Days Post Vaccination 3</measure>
    <time_frame>30 Days after Vaccination 3 (Month 5)</time_frame>
    <description>The concentration of anti-HBsAg was assessed using an enhanced chemiluminescence assay. The protocol-specified analysis of the percentage of participants with anti-HBsAg ≥10 mIU/mL at 30 days post vaccination 3 was conducted in participants combined across vaccine dosing schedules (Group 1 + Group 2) as well as in participants separated across vaccine dosing schedules (Group 1, Group 2). Per protocol, participants with anti-HBsAg ≥10 mIU/mL in Group 5 were compared to Group 1 + Group 2 at 30 days post Vaccination 3, as a pre-specified secondary outcome analysis. Analysis of participants with anti-HBsAg ≥10 mIU/mL was not planned to be reported in Group 3 and Group 4, per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Group 5 Versus Group 1 + Group 2: Geometric Mean Titer (GMT) of Anti-Rotavirus Immunoglobulin A (IgA) at 30 Days Post Vaccination 3</measure>
    <time_frame>30 Days after Vaccination 3 (Month 5)</time_frame>
    <description>The GMT of anti-rotavirus IgA was assessed using a serum IgA enzyme linked immunosorbent assay. The protocol specified analysis of anti-rotavirus IgA GMT at 30 days post vaccination 3 was conducted in participants combined across vaccine dosing schedules (Group 1 + Group 2) as well as in participants separated across vaccine dosing schedules (Group 1, Group 2). Per protocol, GMT of anti-rotavirus IgA in Group 5 was compared to Group 1 + Group 2 at 30 days post Vaccination 3, as a pre-specified secondary outcome analysis. Anti-rotavirus IgA GMT analysis was not planned to be reported in Group 3 and Group 4, per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMC of Anti-PnP IgG for 15 Serotypes Contained in V114 at 30 Days Post Vaccination 3</measure>
    <time_frame>30 Days after Vaccination 3 (Month 5)</time_frame>
    <description>The concentration of anti-PnP serotype-specific IgG for 15 serotypes contained in V114 (13 serotypes shared with Prevnar 13™ [1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] and 2 unique serotypes [22F, 33F]) was assessed using a PnECL assay. Per protocol, GMC of 15 IgG serotypes was assessed at 30 days post Vaccination 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-PnP IgG Concentration ≥0.35 µg/mL for 15 Serotypes Contained in V114 at 30 Days Post Vaccination 3</measure>
    <time_frame>30 Days after Vaccination 3 (Month 5)</time_frame>
    <description>The concentration of anti-PnP serotype-specific IgG for 15 serotypes contained in V114 (13 serotypes shared with Prevnar 13™ [1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] and 2 unique serotypes [22F, 33F]) was assessed using a PnECL assay. Per protocol, percentage of participants with anti-PnP IgG concentrations ≥0.35 µg/mL was assessed at 30 days post Vaccination 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Group 5 Versus Group 1: GMC of Anti-PnP IgG For 13 Shared Serotypes Contained in V114 and Prevnar 13™ at 30 Days Post Vaccination 4</measure>
    <time_frame>30 Days after Vaccination 4 (Months 11-14)</time_frame>
    <description>The GMC of anti-PnP serotype-specific IgG for 13 shared serotypes contained in V114 and Prevnar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) was assessed using a PnECL assay. Per protocol, GMC of 13 IgG serotypes was analysed by vaccine dosing schedules (Groups 1, 5). Per protocol, 13 IgG serotypes in Group 5 (experimental arm) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4 as a pre-specified secondary outcome analysis; 13 IgG serotypes in Groups 2, 3, 4 (experimental arms) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4, as a separate protocol-specified primary outcome analysis and reported earlier in the record.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">900</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Prevnar 13™-V114-V114-V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: V114-V114-V114-V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.</description>
    <arm_group_label>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</arm_group_label>
    <arm_group_label>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</arm_group_label>
    <arm_group_label>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</arm_group_label>
    <arm_group_label>Group 4: Prevnar 13™-V114-V114-V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.</description>
    <arm_group_label>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</arm_group_label>
    <arm_group_label>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</arm_group_label>
    <arm_group_label>Group 4: Prevnar 13™-V114-V114-V114</arm_group_label>
    <arm_group_label>Group 5: V114-V114-V114-V114</arm_group_label>
    <other_name>VAXNEUVANCE™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RotaTeq™</intervention_name>
    <description>RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.</description>
    <arm_group_label>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</arm_group_label>
    <arm_group_label>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</arm_group_label>
    <arm_group_label>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</arm_group_label>
    <arm_group_label>Group 4: Prevnar 13™-V114-V114-V114</arm_group_label>
    <arm_group_label>Group 5: V114-V114-V114-V114</arm_group_label>
    <other_name>V260; trade names of the concomitant vaccines may vary depending on where clinical supplies are sourced.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentacel™</intervention_name>
    <description>Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.</description>
    <arm_group_label>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</arm_group_label>
    <arm_group_label>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</arm_group_label>
    <arm_group_label>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</arm_group_label>
    <arm_group_label>Group 4: Prevnar 13™-V114-V114-V114</arm_group_label>
    <arm_group_label>Group 5: V114-V114-V114-V114</arm_group_label>
    <other_name>Trade names of the concomitant vaccines may vary depending on where clinical supplies are sourced.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RECOMBIVAX HB™</intervention_name>
    <description>RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.</description>
    <arm_group_label>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</arm_group_label>
    <arm_group_label>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</arm_group_label>
    <arm_group_label>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</arm_group_label>
    <arm_group_label>Group 4: Prevnar 13™-V114-V114-V114</arm_group_label>
    <arm_group_label>Group 5: V114-V114-V114-V114</arm_group_label>
    <other_name>V232, HEPTAVAX™-II, HBVAXPRO; trade names of the concomitant vaccines may vary depending on where clinical supplies are sourced.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIBERIX™</intervention_name>
    <description>HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.</description>
    <arm_group_label>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</arm_group_label>
    <arm_group_label>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</arm_group_label>
    <arm_group_label>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</arm_group_label>
    <arm_group_label>Group 4: Prevnar 13™-V114-V114-V114</arm_group_label>
    <arm_group_label>Group 5: V114-V114-V114-V114</arm_group_label>
    <other_name>Trade names of the concomitant vaccines may vary depending on where clinical supplies are sourced.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-M-R™ II</intervention_name>
    <description>M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.</description>
    <arm_group_label>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</arm_group_label>
    <arm_group_label>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</arm_group_label>
    <arm_group_label>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</arm_group_label>
    <arm_group_label>Group 4: Prevnar 13™-V114-V114-V114</arm_group_label>
    <arm_group_label>Group 5: V114-V114-V114-V114</arm_group_label>
    <other_name>V205C; trade names of the concomitant vaccines may vary depending on where clinical supplies are sourced.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VARIVAX™</intervention_name>
    <description>VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.</description>
    <arm_group_label>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</arm_group_label>
    <arm_group_label>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</arm_group_label>
    <arm_group_label>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</arm_group_label>
    <arm_group_label>Group 4: Prevnar 13™-V114-V114-V114</arm_group_label>
    <arm_group_label>Group 5: V114-V114-V114-V114</arm_group_label>
    <other_name>V210; trade names of the concomitant vaccines may vary depending on where clinical supplies are sourced.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is Healthy, based on clinical judgment of the investigator&#xD;
&#xD;
          -  Has a legally acceptable representative who understands the study procedures,&#xD;
             alternate treatments available, and risks involved with the study and voluntarily&#xD;
             agrees to participate by giving written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of invasive pneumococcal disease (positive blood culture, positive&#xD;
             cerebrospinal fluid culture, or other sterile site) or known history of other culture&#xD;
             positive pneumococcal disease&#xD;
&#xD;
          -  Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine&#xD;
             (PCV), any component of the licensed pediatric vaccines to be administered&#xD;
             concomitantly in the study, or any diphtheria toxoid-containing vaccine&#xD;
&#xD;
          -  Has any contraindication to the concomitant study vaccines being administered in the&#xD;
             study&#xD;
&#xD;
          -  Has a known or suspected impairment of immunological function&#xD;
&#xD;
          -  Has a history of congenital or acquired immunodeficiency&#xD;
&#xD;
          -  Has or his/her mother has a documented human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Has or his/her mother has a documented hepatitis B surface antigen - positive test&#xD;
&#xD;
          -  Has known or history of functional or anatomic asplenia&#xD;
&#xD;
          -  Has failure to thrive based on the clinical judgment of the investigator&#xD;
&#xD;
          -  Has a known coagulation disorder contraindicating intramuscular vaccination&#xD;
&#xD;
          -  Has a history of autoimmune disease (including but not limited to systemic lupus&#xD;
             erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid&#xD;
             disease, polymyositis and dermatomyositis, scleroderma, type 1 diabetes mellitus, or&#xD;
             other autoimmune disorders)&#xD;
&#xD;
          -  Has a known neurologic or cognitive behavioral disorder, including&#xD;
             encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development&#xD;
             disorder, and related disorders&#xD;
&#xD;
          -  Has received a dose of any pneumococcal vaccine prior to study entry&#xD;
&#xD;
          -  Has received &gt;1 dose of monovalent hepatitis B vaccine or hepatitis B based&#xD;
             combination vaccine prior to study entry&#xD;
&#xD;
          -  Has received a dose of rotavirus vaccine prior to study entry&#xD;
&#xD;
          -  Has received a blood transfusion or blood products, including immunoglobulins&#xD;
&#xD;
          -  Has participated in another clinical study of an investigational product before the&#xD;
             beginning or anytime during the duration of the current clinical study&#xD;
&#xD;
          -  Has any other reason that, in the opinion of the investigator, may interfere with the&#xD;
             evaluation required by the study&#xD;
&#xD;
          -  Has an immediate family member (e.g., parent/legal guardian or sibling) who is&#xD;
             investigational site or Sponsor staff directly involved with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics ( Site 0015)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Pediatric Associates, P.A. ( Site 0002)</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Clinic of Jonesboro, PA ( Site 0022)</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davita Medical Group ( Site 0012)</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Associates, LLC ( Site 0035)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33184</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research Inc ( Site 0011)</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Fall River ( Site 0021)</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Health Research Institute, LLC ( Site 0024)</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Health Research Institute, LLC ( Site 0003)</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Health Research Institute, LLC ( Site 0004)</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Health Research Institute, LLC ( Site 0001)</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summerwood Pediatrics ( Site 0009)</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center ( Site 0029)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University ( Site 0008)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare, PA ( Site 0025)</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research ( Site 0006)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkside Pediatric ( Site 0007)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group ( Site 0018)</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group LLC ( Site 0017)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch ( Site 0023)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Pediatrics-Cottonwood Office ( Site 0014)</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare ( Site 0019)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooperativa de Facultad Medica Sanacoop ( Site 0057)</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Puerto Rico ( Site 0050)</name>
      <address>
        <city>Guayama</city>
        <zip>00784</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAIMED Center - Ponce School of Medicine ( Site 0053)</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Hospital ( Site 0056)</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico ( Site 0051)</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital. Khon Kaen University ( Site 0093)</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University ( Site 0092)</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriaj Hospital ( Site 0091)</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital ( Site 0090)</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Faculty of Medicine ( Site 0070)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi University Faculty of Medicine ( Site 0071)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty Hospital ( Site 0072)</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <results_first_submitted>July 28, 2021</results_first_submitted>
  <results_first_submitted_qc>July 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03620162/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were screened at Study Day 1, prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
          <description>Participants received a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="P4">
          <title>Group 4: Prevnar 13™-V114-V114-V114</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="P5">
          <title>Group 5: V114-V114-V114-V114</title>
          <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="181"/>
                <participants group_id="P3" count="180"/>
                <participants group_id="P4" count="180"/>
                <participants group_id="P5" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1 (V114 or Prevnar 13™)</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="181"/>
                <participants group_id="P3" count="178"/>
                <participants group_id="P4" count="179"/>
                <participants group_id="P5" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2 (V114 or Prevnar 13™)</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="175"/>
                <participants group_id="P3" count="166"/>
                <participants group_id="P4" count="169"/>
                <participants group_id="P5" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 3 (V114 or Prevnar 13™)</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="161"/>
                <participants group_id="P4" count="167"/>
                <participants group_id="P5" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 4 (V114 or Prevnar 13™)</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="150"/>
                <participants group_id="P4" count="162"/>
                <participants group_id="P5" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="147"/>
                <participants group_id="P4" count="160"/>
                <participants group_id="P5" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn by parent/guardian</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
          <description>Participants received a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="B4">
          <title>Group 4: Prevnar 13™-V114-V114-V114</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="B5">
          <title>Group 5: V114-V114-V114-V114</title>
          <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="179"/>
            <count group_id="B2" value="181"/>
            <count group_id="B3" value="180"/>
            <count group_id="B4" value="180"/>
            <count group_id="B5" value="180"/>
            <count group_id="B6" value="900"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="7.8"/>
                    <measurement group_id="B2" value="63.6" spread="8.4"/>
                    <measurement group_id="B3" value="62.7" spread="9.1"/>
                    <measurement group_id="B4" value="63.4" spread="9.3"/>
                    <measurement group_id="B5" value="64.0" spread="9.3"/>
                    <measurement group_id="B6" value="63.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="88"/>
                    <measurement group_id="B6" value="426"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="92"/>
                    <measurement group_id="B6" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="213"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="136"/>
                    <measurement group_id="B5" value="137"/>
                    <measurement group_id="B6" value="686"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="104"/>
                    <measurement group_id="B6" value="553"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Solicited Injection-site Adverse Event (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, the percentage of participants with solicited injection-site AEs was assessed for up to ~14 days after each vaccination. The solicited injection-site AEs assessed were erythema/redness, induration/hard lump, tenderness/pain and swelling.</description>
        <time_frame>Up to ~14 days after each vaccination</time_frame>
        <population>All randomized participants who got ≥1 dose of V114 or Prevnar 13™.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Prevnar 13™-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: V114-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Solicited Injection-site Adverse Event (AE)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, the percentage of participants with solicited injection-site AEs was assessed for up to ~14 days after each vaccination. The solicited injection-site AEs assessed were erythema/redness, induration/hard lump, tenderness/pain and swelling.</description>
          <population>All randomized participants who got ≥1 dose of V114 or Prevnar 13™.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="179"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema/Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5"/>
                    <measurement group_id="O2" value="37.6"/>
                    <measurement group_id="O3" value="38.8"/>
                    <measurement group_id="O4" value="43.0"/>
                    <measurement group_id="O5" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration/Hard lump</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="26.0"/>
                    <measurement group_id="O3" value="28.1"/>
                    <measurement group_id="O4" value="25.1"/>
                    <measurement group_id="O5" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness/Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1"/>
                    <measurement group_id="O2" value="43.6"/>
                    <measurement group_id="O3" value="46.1"/>
                    <measurement group_id="O4" value="43.6"/>
                    <measurement group_id="O5" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="24.7"/>
                    <measurement group_id="O4" value="20.7"/>
                    <measurement group_id="O5" value="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Erythema(Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, confidence intervals (CIs), and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.525</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.6</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Erythema(Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.396</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.7</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Erythema(Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.097</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-8.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.8</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Erythema(Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.057</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.9</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Induration(Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.085</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-8.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.8</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Induration(Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.050</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.9</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Induration(Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.183</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.1</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Induration(Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.074</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-8.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.1</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Tenderness(Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.525</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Tenderness(Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.915</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Tenderness(Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.714</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Tenderness(Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.926</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.7</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Swelling(Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>&gt; 0.999</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Swelling(Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.609</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Swelling(Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.688</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Swelling(Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.336</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.6</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Solicited Systemic AE</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, the percentage of participants with solicited systemic AEs was assessed for up to ~14 days after each vaccination. The solicited systemic AEs assessed were appetite lost/decreased appetite, irritability, drowsiness/somnolence and hives or welts/urticaria.</description>
        <time_frame>Up to ~14 days after each vaccination</time_frame>
        <population>All randomized participants who got ≥1 dose of V114 or Prevnar 13™.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Prevnar 13™-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: V114-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Solicited Systemic AE</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, the percentage of participants with solicited systemic AEs was assessed for up to ~14 days after each vaccination. The solicited systemic AEs assessed were appetite lost/decreased appetite, irritability, drowsiness/somnolence and hives or welts/urticaria.</description>
          <population>All randomized participants who got ≥1 dose of V114 or Prevnar 13™.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="179"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Appetite lost/Decreased Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="32.0"/>
                    <measurement group_id="O3" value="27.0"/>
                    <measurement group_id="O4" value="35.2"/>
                    <measurement group_id="O5" value="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6"/>
                    <measurement group_id="O2" value="60.8"/>
                    <measurement group_id="O3" value="62.9"/>
                    <measurement group_id="O4" value="68.2"/>
                    <measurement group_id="O5" value="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness/Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="56.7"/>
                    <measurement group_id="O4" value="57.0"/>
                    <measurement group_id="O5" value="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives/Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="8.9"/>
                    <measurement group_id="O5" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage:Appetite lost(Group5 vs1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.825</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.0</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage:Appetite lost(Group4 vs1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.912</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>9.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage:Appetite lost(Group3 vs1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.074</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.3</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage:Appetite lost(Group2 vs1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.458</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Percentage of Participants</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.4</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage:Irritability(Group 5 vs1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.568</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage:Irritability(Group 4 vs1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.910</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage:Irritability(Group 3 vs1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.354</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.5</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage:Irritability(Group 2 vs1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.178</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.6</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Drowsiness(Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.520</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>13.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Drowsiness(Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>&gt; 0.999</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Drowsiness(Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.963</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Drowsiness(Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.821</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Hives(Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.836</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Hives(Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.562</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Hives(Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.527</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage: Hives(Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences, CIs, and p-values are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <p_value>= 0.160</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.6</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)</title>
        <description>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgement. Relatedness of an SAE to the study vaccine was determined by the investigator. Per protocol, the percentage of participants with vaccine-related SAEs was assessed through 6 months following Vaccination 4.</description>
        <time_frame>Up to ~6 months after Vaccination 4 (up to ~19 months)</time_frame>
        <population>All randomized participants who got ≥1 dose of V114 or Prevnar 13™.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Prevnar 13™-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: V114-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)</title>
          <description>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgement. Relatedness of an SAE to the study vaccine was determined by the investigator. Per protocol, the percentage of participants with vaccine-related SAEs was assessed through 6 months following Vaccination 4.</description>
          <population>All randomized participants who got ≥1 dose of V114 or Prevnar 13™.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="179"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences and CIs are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences and CIs are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences and CIs are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimated differences and CIs are calculated based on the Miettinen &amp; Nurminen method and are provided in accordance with the statistical analysis plan.</non_inferiority_desc>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) of Anti-Pneumococcal Polysaccharide (PnP) Immunoglobulin G (IgG) For 13 Shared Serotypes Contained in V114 and Prevnar 13™ at 30 Days Post Vaccination 4</title>
        <description>The GMC of anti-PnP serotype-specific IgG for 13 shared serotypes contained in V114 and Prevnar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) was assessed using a pneumococcal electrochemiluminescence (PnECL) assay. Per protocol, 13 IgG serotypes in Groups 2, 3, 4 (experimental arms) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4 as a pre-specified primary outcome analysis; 13 IgG serotypes in Group 5 (experimental arm) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4, as a separate protocol-specified secondary outcome analysis and reported later in the record.</description>
        <time_frame>30 Days after Vaccination 4 (Months 11-14)</time_frame>
        <population>All randomized participants who were compliant with the protocol, got scheduled dosing of V114 or Prevnar 13™ and had IgG GMC data for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F or 23F in Groups 1, 2, 3, 4 or 5 at 30 Days post Vaccination 4. 13 IgG serotypes in Groups 2, 3, 4 were compared to Group 1 as a protocol-specified primary outcome analysis; 13 IgG serotypes in Group 5 were compared to Group 1 as a separate protocol-specified secondary outcome analysis and reported later.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Prevnar 13™-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: V114-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Anti-Pneumococcal Polysaccharide (PnP) Immunoglobulin G (IgG) For 13 Shared Serotypes Contained in V114 and Prevnar 13™ at 30 Days Post Vaccination 4</title>
          <description>The GMC of anti-PnP serotype-specific IgG for 13 shared serotypes contained in V114 and Prevnar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) was assessed using a pneumococcal electrochemiluminescence (PnECL) assay. Per protocol, 13 IgG serotypes in Groups 2, 3, 4 (experimental arms) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4 as a pre-specified primary outcome analysis; 13 IgG serotypes in Group 5 (experimental arm) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4, as a separate protocol-specified secondary outcome analysis and reported later in the record.</description>
          <population>All randomized participants who were compliant with the protocol, got scheduled dosing of V114 or Prevnar 13™ and had IgG GMC data for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F or 23F in Groups 1, 2, 3, 4 or 5 at 30 Days post Vaccination 4. 13 IgG serotypes in Groups 2, 3, 4 were compared to Group 1 as a protocol-specified primary outcome analysis; 13 IgG serotypes in Group 5 were compared to Group 1 as a separate protocol-specified secondary outcome analysis and reported later.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="179"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.78" upper_limit="2.30"/>
                    <measurement group_id="O2" value="1.69" lower_limit="1.48" upper_limit="1.93"/>
                    <measurement group_id="O3" value="1.89" lower_limit="1.63" upper_limit="2.18"/>
                    <measurement group_id="O4" value="1.68" lower_limit="1.48" upper_limit="1.91"/>
                    <measurement group_id="O5" value="1.46" lower_limit="1.30" upper_limit="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.64" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.68" upper_limit="0.87"/>
                    <measurement group_id="O3" value="0.68" lower_limit="0.61" upper_limit="0.77"/>
                    <measurement group_id="O4" value="0.73" lower_limit="0.66" upper_limit="0.82"/>
                    <measurement group_id="O5" value="0.89" lower_limit="0.79" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.30" upper_limit="1.76"/>
                    <measurement group_id="O2" value="1.33" lower_limit="1.14" upper_limit="1.56"/>
                    <measurement group_id="O3" value="1.27" lower_limit="1.10" upper_limit="1.46"/>
                    <measurement group_id="O4" value="1.23" lower_limit="1.08" upper_limit="1.41"/>
                    <measurement group_id="O5" value="1.35" lower_limit="1.17" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" lower_limit="3.18" upper_limit="4.20"/>
                    <measurement group_id="O2" value="3.39" lower_limit="2.91" upper_limit="3.94"/>
                    <measurement group_id="O3" value="3.82" lower_limit="3.23" upper_limit="4.51"/>
                    <measurement group_id="O4" value="2.90" lower_limit="2.50" upper_limit="3.38"/>
                    <measurement group_id="O5" value="2.90" lower_limit="2.50" upper_limit="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" lower_limit="5.56" upper_limit="7.42"/>
                    <measurement group_id="O2" value="7.16" lower_limit="6.30" upper_limit="8.15"/>
                    <measurement group_id="O3" value="7.16" lower_limit="6.17" upper_limit="8.30"/>
                    <measurement group_id="O4" value="5.17" lower_limit="4.43" upper_limit="6.03"/>
                    <measurement group_id="O5" value="4.43" lower_limit="3.86" upper_limit="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" lower_limit="5.36" upper_limit="7.07"/>
                    <measurement group_id="O2" value="7.58" lower_limit="6.61" upper_limit="8.68"/>
                    <measurement group_id="O3" value="6.64" lower_limit="5.73" upper_limit="7.69"/>
                    <measurement group_id="O4" value="6.62" lower_limit="5.75" upper_limit="7.62"/>
                    <measurement group_id="O5" value="5.83" lower_limit="5.09" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" lower_limit="4.43" upper_limit="5.88"/>
                    <measurement group_id="O2" value="5.69" lower_limit="4.93" upper_limit="6.56"/>
                    <measurement group_id="O3" value="5.06" lower_limit="4.33" upper_limit="5.92"/>
                    <measurement group_id="O4" value="3.98" lower_limit="3.47" upper_limit="4.57"/>
                    <measurement group_id="O5" value="3.43" lower_limit="3.02" upper_limit="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="2.56" upper_limit="3.34"/>
                    <measurement group_id="O2" value="2.76" lower_limit="2.41" upper_limit="3.16"/>
                    <measurement group_id="O3" value="2.57" lower_limit="2.22" upper_limit="2.97"/>
                    <measurement group_id="O4" value="2.46" lower_limit="2.19" upper_limit="2.78"/>
                    <measurement group_id="O5" value="2.89" lower_limit="2.56" upper_limit="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" lower_limit="6.55" upper_limit="8.86"/>
                    <measurement group_id="O2" value="10.59" lower_limit="9.01" upper_limit="12.44"/>
                    <measurement group_id="O3" value="10.91" lower_limit="9.29" upper_limit="12.81"/>
                    <measurement group_id="O4" value="7.87" lower_limit="6.77" upper_limit="9.16"/>
                    <measurement group_id="O5" value="6.57" lower_limit="5.73" upper_limit="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" lower_limit="2.21" upper_limit="2.99"/>
                    <measurement group_id="O2" value="3.88" lower_limit="3.38" upper_limit="4.45"/>
                    <measurement group_id="O3" value="3.70" lower_limit="3.20" upper_limit="4.29"/>
                    <measurement group_id="O4" value="2.76" lower_limit="2.42" upper_limit="3.15"/>
                    <measurement group_id="O5" value="2.65" lower_limit="2.34" upper_limit="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" lower_limit="5.15" upper_limit="6.80"/>
                    <measurement group_id="O2" value="5.52" lower_limit="4.88" upper_limit="6.25"/>
                    <measurement group_id="O3" value="5.20" lower_limit="4.42" upper_limit="6.12"/>
                    <measurement group_id="O4" value="4.95" lower_limit="4.27" upper_limit="5.73"/>
                    <measurement group_id="O5" value="4.66" lower_limit="4.15" upper_limit="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="139"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" lower_limit="4.22" upper_limit="5.42"/>
                    <measurement group_id="O2" value="4.88" lower_limit="4.33" upper_limit="5.51"/>
                    <measurement group_id="O3" value="5.02" lower_limit="4.40" upper_limit="5.73"/>
                    <measurement group_id="O4" value="4.60" lower_limit="4.00" upper_limit="5.28"/>
                    <measurement group_id="O5" value="4.10" lower_limit="3.66" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="127"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" lower_limit="2.42" upper_limit="3.44"/>
                    <measurement group_id="O2" value="2.72" lower_limit="2.33" upper_limit="3.18"/>
                    <measurement group_id="O3" value="2.29" lower_limit="1.93" upper_limit="2.70"/>
                    <measurement group_id="O4" value="2.22" lower_limit="1.92" upper_limit="2.56"/>
                    <measurement group_id="O5" value="2.11" lower_limit="1.81" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 1 (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 1 (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 1 (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 3 (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 3 (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 3 (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 4 (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 4 (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 4 (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 5 (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 5 (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 5 (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 6A (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 6A (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 6A (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 6B (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 6B (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 6B (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 7F (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 7F (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 7F (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 9V (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 9V (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 9V (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 14 (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 14 (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 14 (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 18C (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 18C (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 18C (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 19A (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 19A (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 19A (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 19F (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 19F (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 19F (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 23F (Group 4 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 23F (Group 3 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 23F (Group 2 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Group 5 Versus Group 1 + Group 2: Percentage of Participants With Anti-Hepatitis B Surface Antigen (HBsAg) ≥10 mIU/mL at 30 Days Post Vaccination 3</title>
        <description>The concentration of anti-HBsAg was assessed using an enhanced chemiluminescence assay. The protocol-specified analysis of the percentage of participants with anti-HBsAg ≥10 mIU/mL at 30 days post vaccination 3 was conducted in participants combined across vaccine dosing schedules (Group 1 + Group 2) as well as in participants separated across vaccine dosing schedules (Group 1, Group 2). Per protocol, participants with anti-HBsAg ≥10 mIU/mL in Group 5 were compared to Group 1 + Group 2 at 30 days post Vaccination 3, as a pre-specified secondary outcome analysis. Analysis of participants with anti-HBsAg ≥10 mIU/mL was not planned to be reported in Group 3 and Group 4, per protocol.</description>
        <time_frame>30 Days after Vaccination 3 (Month 5)</time_frame>
        <population>All randomized participants who were protocol compliant, got scheduled dosing of V114, Prevnar 13™ or background RECOMBIVAX HB™, had anti-HBsAg data at 30 days post Vaccination 3. Per protocol anti-HBsAg analysis was done in participants combined across dosing schedules (Group 1 + 2) and separated across dosing schedules (Group 1, 2). Per protocol Group 5 was compared to Group 1 + 2 as a secondary outcome analysis. Per protocol anti-HBsAg analysis was not planned to be reported in Groups 3, 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Prevnar 13™-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: V114-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O6">
            <title>Group 1: Prevnar 13™(Vaccinations 1-4) + Group 2: Prevnar 13™(Vaccinations 1-3)-V114 (Vaccination 4)</title>
            <description>Group 1 participants who received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3), Months 10-13 (Vaccination 4) and Group 2 participants who received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4), were combined across vaccination schedule. Group 1 plus Group 2 participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
        </group_list>
        <measure>
          <title>Group 5 Versus Group 1 + Group 2: Percentage of Participants With Anti-Hepatitis B Surface Antigen (HBsAg) ≥10 mIU/mL at 30 Days Post Vaccination 3</title>
          <description>The concentration of anti-HBsAg was assessed using an enhanced chemiluminescence assay. The protocol-specified analysis of the percentage of participants with anti-HBsAg ≥10 mIU/mL at 30 days post vaccination 3 was conducted in participants combined across vaccine dosing schedules (Group 1 + Group 2) as well as in participants separated across vaccine dosing schedules (Group 1, Group 2). Per protocol, participants with anti-HBsAg ≥10 mIU/mL in Group 5 were compared to Group 1 + Group 2 at 30 days post Vaccination 3, as a pre-specified secondary outcome analysis. Analysis of participants with anti-HBsAg ≥10 mIU/mL was not planned to be reported in Group 3 and Group 4, per protocol.</description>
          <population>All randomized participants who were protocol compliant, got scheduled dosing of V114, Prevnar 13™ or background RECOMBIVAX HB™, had anti-HBsAg data at 30 days post Vaccination 3. Per protocol anti-HBsAg analysis was done in participants combined across dosing schedules (Group 1 + 2) and separated across dosing schedules (Group 1, 2). Per protocol Group 5 was compared to Group 1 + 2 as a secondary outcome analysis. Per protocol anti-HBsAg analysis was not planned to be reported in Groups 3, 4.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="153"/>
                <count group_id="O6" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                    <measurement group_id="O2" value="99.3"/>
                    <measurement group_id="O5" value="98.7"/>
                    <measurement group_id="O6" value="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Difference in Percentage (Group 5 vs Group 1+2)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The statistical criterion for non-inferiority requires the lower bound of the 2-sided 95% CI for the difference in percentages (Group 5/Group 1+Group 2) to be &gt;-10 percentage points.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Group 5 Versus Group 1 + Group 2: Geometric Mean Titer (GMT) of Anti-Rotavirus Immunoglobulin A (IgA) at 30 Days Post Vaccination 3</title>
        <description>The GMT of anti-rotavirus IgA was assessed using a serum IgA enzyme linked immunosorbent assay. The protocol specified analysis of anti-rotavirus IgA GMT at 30 days post vaccination 3 was conducted in participants combined across vaccine dosing schedules (Group 1 + Group 2) as well as in participants separated across vaccine dosing schedules (Group 1, Group 2). Per protocol, GMT of anti-rotavirus IgA in Group 5 was compared to Group 1 + Group 2 at 30 days post Vaccination 3, as a pre-specified secondary outcome analysis. Anti-rotavirus IgA GMT analysis was not planned to be reported in Group 3 and Group 4, per protocol.</description>
        <time_frame>30 Days after Vaccination 3 (Month 5)</time_frame>
        <population>All randomized participants who were protocol compliant, got scheduled dosing of V114, Prevnar 13™ or background RotaTeq™, had anti-rotavirus data at 30 days post Vaccination 3. Per protocol anti-rotavirus analysis was done in participants combined across dosing schedules (Group 1 + 2) and separated across dosing schedules (Group 1, 2). Per protocol Group 5 was compared to Group 1 + 2 as a secondary outcome analysis. Per protocol anti-rotavirus analysis was not planned or reported in Group 3, 4</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Prevnar 13™-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: V114-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O6">
            <title>Group 1: Prevnar 13™(Vaccinations 1-4) + Group 2: Prevnar 13™(Vaccinations 1-3)-V114 (Vaccination 4)</title>
            <description>Group 1 participants who received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3), Months 10-13 (Vaccination 4) and Group 2 participants who received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4), were combined across vaccination schedule. Group 1 plus Group 2 participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
        </group_list>
        <measure>
          <title>Group 5 Versus Group 1 + Group 2: Geometric Mean Titer (GMT) of Anti-Rotavirus Immunoglobulin A (IgA) at 30 Days Post Vaccination 3</title>
          <description>The GMT of anti-rotavirus IgA was assessed using a serum IgA enzyme linked immunosorbent assay. The protocol specified analysis of anti-rotavirus IgA GMT at 30 days post vaccination 3 was conducted in participants combined across vaccine dosing schedules (Group 1 + Group 2) as well as in participants separated across vaccine dosing schedules (Group 1, Group 2). Per protocol, GMT of anti-rotavirus IgA in Group 5 was compared to Group 1 + Group 2 at 30 days post Vaccination 3, as a pre-specified secondary outcome analysis. Anti-rotavirus IgA GMT analysis was not planned to be reported in Group 3 and Group 4, per protocol.</description>
          <population>All randomized participants who were protocol compliant, got scheduled dosing of V114, Prevnar 13™ or background RotaTeq™, had anti-rotavirus data at 30 days post Vaccination 3. Per protocol anti-rotavirus analysis was done in participants combined across dosing schedules (Group 1 + 2) and separated across dosing schedules (Group 1, 2). Per protocol Group 5 was compared to Group 1 + 2 as a secondary outcome analysis. Per protocol anti-rotavirus analysis was not planned or reported in Group 3, 4</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="152"/>
                <count group_id="O6" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286.5" lower_limit="218.1" upper_limit="376.2"/>
                    <measurement group_id="O2" value="329.5" lower_limit="254.9" upper_limit="426.1"/>
                    <measurement group_id="O5" value="298.3" lower_limit="228.2" upper_limit="390.0"/>
                    <measurement group_id="O6" value="307.0" lower_limit="254.7" upper_limit="369.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio (Group 5 vs Group 1+2)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The statistical criterion for non-inferiority requires the lower bound of the 2-sided 95% CI for the GMT ratio (Group 5/Group 1+Group 2) to be &gt;0.5.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>GMT Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMC of Anti-PnP IgG for 15 Serotypes Contained in V114 at 30 Days Post Vaccination 3</title>
        <description>The concentration of anti-PnP serotype-specific IgG for 15 serotypes contained in V114 (13 serotypes shared with Prevnar 13™ [1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] and 2 unique serotypes [22F, 33F]) was assessed using a PnECL assay. Per protocol, GMC of 15 IgG serotypes was assessed at 30 days post Vaccination 3.</description>
        <time_frame>30 Days after Vaccination 3 (Month 5)</time_frame>
        <population>All randomized participants who were compliant with the protocol, got scheduled dosing of V114 or Prevnar 13™, had IgG GMC data available for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F or 33F in Groups 1, 2, 3, 4 or 5 at 30 Days post Vaccination 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Prevnar 13™-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: V114-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
        </group_list>
        <measure>
          <title>GMC of Anti-PnP IgG for 15 Serotypes Contained in V114 at 30 Days Post Vaccination 3</title>
          <description>The concentration of anti-PnP serotype-specific IgG for 15 serotypes contained in V114 (13 serotypes shared with Prevnar 13™ [1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] and 2 unique serotypes [22F, 33F]) was assessed using a PnECL assay. Per protocol, GMC of 15 IgG serotypes was assessed at 30 days post Vaccination 3.</description>
          <population>All randomized participants who were compliant with the protocol, got scheduled dosing of V114 or Prevnar 13™, had IgG GMC data available for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F or 33F in Groups 1, 2, 3, 4 or 5 at 30 Days post Vaccination 3.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="179"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" lower_limit="1.69" upper_limit="2.20"/>
                    <measurement group_id="O2" value="1.99" lower_limit="1.78" upper_limit="2.21"/>
                    <measurement group_id="O3" value="1.86" lower_limit="1.64" upper_limit="2.10"/>
                    <measurement group_id="O4" value="1.35" lower_limit="1.19" upper_limit="1.53"/>
                    <measurement group_id="O5" value="1.27" lower_limit="1.14" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.47" upper_limit="0.61"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.56" upper_limit="0.73"/>
                    <measurement group_id="O3" value="0.56" lower_limit="0.49" upper_limit="0.63"/>
                    <measurement group_id="O4" value="0.67" lower_limit="0.60" upper_limit="0.76"/>
                    <measurement group_id="O5" value="1.01" lower_limit="0.91" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" lower_limit="1.22" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1.47" lower_limit="1.30" upper_limit="1.66"/>
                    <measurement group_id="O3" value="1.34" lower_limit="1.14" upper_limit="1.56"/>
                    <measurement group_id="O4" value="1.07" lower_limit="0.93" upper_limit="1.22"/>
                    <measurement group_id="O5" value="1.40" lower_limit="1.24" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="1.69" upper_limit="2.34"/>
                    <measurement group_id="O2" value="2.16" lower_limit="1.87" upper_limit="2.49"/>
                    <measurement group_id="O3" value="2.15" lower_limit="1.83" upper_limit="2.52"/>
                    <measurement group_id="O4" value="1.73" lower_limit="1.50" upper_limit="1.99"/>
                    <measurement group_id="O5" value="1.91" lower_limit="1.67" upper_limit="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" lower_limit="2.66" upper_limit="3.54"/>
                    <measurement group_id="O2" value="3.22" lower_limit="2.83" upper_limit="3.67"/>
                    <measurement group_id="O3" value="3.26" lower_limit="2.79" upper_limit="3.82"/>
                    <measurement group_id="O4" value="2.05" lower_limit="1.76" upper_limit="2.38"/>
                    <measurement group_id="O5" value="1.82" lower_limit="1.59" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="127"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" lower_limit="1.66" upper_limit="2.49"/>
                    <measurement group_id="O2" value="2.50" lower_limit="2.10" upper_limit="2.99"/>
                    <measurement group_id="O3" value="2.43" lower_limit="2.05" upper_limit="2.88"/>
                    <measurement group_id="O4" value="2.29" lower_limit="1.91" upper_limit="2.76"/>
                    <measurement group_id="O5" value="2.26" lower_limit="1.87" upper_limit="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" lower_limit="2.99" upper_limit="3.77"/>
                    <measurement group_id="O2" value="3.54" lower_limit="3.16" upper_limit="3.96"/>
                    <measurement group_id="O3" value="3.52" lower_limit="3.10" upper_limit="3.99"/>
                    <measurement group_id="O4" value="2.61" lower_limit="2.33" upper_limit="2.94"/>
                    <measurement group_id="O5" value="2.41" lower_limit="2.17" upper_limit="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.48" upper_limit="1.94"/>
                    <measurement group_id="O2" value="1.81" lower_limit="1.60" upper_limit="2.05"/>
                    <measurement group_id="O3" value="1.68" lower_limit="1.44" upper_limit="1.97"/>
                    <measurement group_id="O4" value="1.47" lower_limit="1.28" upper_limit="1.67"/>
                    <measurement group_id="O5" value="2.01" lower_limit="1.80" upper_limit="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.57" lower_limit="5.55" upper_limit="7.79"/>
                    <measurement group_id="O2" value="6.18" lower_limit="5.22" upper_limit="7.31"/>
                    <measurement group_id="O3" value="9.32" lower_limit="7.45" upper_limit="11.67"/>
                    <measurement group_id="O4" value="6.71" lower_limit="5.76" upper_limit="7.83"/>
                    <measurement group_id="O5" value="5.50" lower_limit="4.79" upper_limit="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.46" upper_limit="1.95"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.81" upper_limit="2.28"/>
                    <measurement group_id="O3" value="2.08" lower_limit="1.81" upper_limit="2.38"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.33" upper_limit="1.71"/>
                    <measurement group_id="O5" value="1.51" lower_limit="1.34" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" lower_limit="1.92" upper_limit="2.47"/>
                    <measurement group_id="O2" value="2.46" lower_limit="2.21" upper_limit="2.74"/>
                    <measurement group_id="O3" value="2.25" lower_limit="1.95" upper_limit="2.60"/>
                    <measurement group_id="O4" value="1.64" lower_limit="1.43" upper_limit="1.87"/>
                    <measurement group_id="O5" value="1.63" lower_limit="1.47" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="2.51" upper_limit="3.18"/>
                    <measurement group_id="O2" value="2.90" lower_limit="2.61" upper_limit="3.23"/>
                    <measurement group_id="O3" value="3.08" lower_limit="2.72" upper_limit="3.48"/>
                    <measurement group_id="O4" value="2.32" lower_limit="2.06" upper_limit="2.62"/>
                    <measurement group_id="O5" value="2.21" lower_limit="2.00" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="135"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.09" upper_limit="1.59"/>
                    <measurement group_id="O2" value="1.72" lower_limit="1.49" upper_limit="1.99"/>
                    <measurement group_id="O3" value="1.22" lower_limit="1.02" upper_limit="1.45"/>
                    <measurement group_id="O4" value="1.33" lower_limit="1.14" upper_limit="1.57"/>
                    <measurement group_id="O5" value="1.46" lower_limit="1.25" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                    <measurement group_id="O3" value="3.63" lower_limit="2.91" upper_limit="4.52"/>
                    <measurement group_id="O4" value="5.94" lower_limit="5.13" upper_limit="6.88"/>
                    <measurement group_id="O5" value="5.15" lower_limit="4.52" upper_limit="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="127"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.05" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.05" upper_limit="0.06"/>
                    <measurement group_id="O3" value="0.28" lower_limit="0.21" upper_limit="0.36"/>
                    <measurement group_id="O4" value="0.89" lower_limit="0.70" upper_limit="1.14"/>
                    <measurement group_id="O5" value="2.22" lower_limit="1.86" upper_limit="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-PnP IgG Concentration ≥0.35 µg/mL for 15 Serotypes Contained in V114 at 30 Days Post Vaccination 3</title>
        <description>The concentration of anti-PnP serotype-specific IgG for 15 serotypes contained in V114 (13 serotypes shared with Prevnar 13™ [1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] and 2 unique serotypes [22F, 33F]) was assessed using a PnECL assay. Per protocol, percentage of participants with anti-PnP IgG concentrations ≥0.35 µg/mL was assessed at 30 days post Vaccination 3.</description>
        <time_frame>30 Days after Vaccination 3 (Month 5)</time_frame>
        <population>All randomized participants who were compliant with the protocol, got scheduled dosing of V114 or Prevnar 13™, had IgG concentration ≥0.35µg/mL data available for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F or 33F in Groups 1, 2, 3, 4 or 5 at 30 Days post Vaccination 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Prevnar 13™-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: V114-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-PnP IgG Concentration ≥0.35 µg/mL for 15 Serotypes Contained in V114 at 30 Days Post Vaccination 3</title>
          <description>The concentration of anti-PnP serotype-specific IgG for 15 serotypes contained in V114 (13 serotypes shared with Prevnar 13™ [1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] and 2 unique serotypes [22F, 33F]) was assessed using a PnECL assay. Per protocol, percentage of participants with anti-PnP IgG concentrations ≥0.35 µg/mL was assessed at 30 days post Vaccination 3.</description>
          <population>All randomized participants who were compliant with the protocol, got scheduled dosing of V114 or Prevnar 13™, had IgG concentration ≥0.35µg/mL data available for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F or 33F in Groups 1, 2, 3, 4 or 5 at 30 Days post Vaccination 3.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="179"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="94.0" upper_limit="99.6"/>
                    <measurement group_id="O2" value="100" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.2" lower_limit="95.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.8" lower_limit="93.8" upper_limit="99.5"/>
                    <measurement group_id="O5" value="96.6" lower_limit="92.3" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" lower_limit="65.2" upper_limit="80.3"/>
                    <measurement group_id="O2" value="73.9" lower_limit="65.9" upper_limit="80.9"/>
                    <measurement group_id="O3" value="79.1" lower_limit="71.0" upper_limit="85.7"/>
                    <measurement group_id="O4" value="81.9" lower_limit="74.4" upper_limit="87.9"/>
                    <measurement group_id="O5" value="93.9" lower_limit="88.7" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="93.9" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.6" lower_limit="94.9" upper_limit="99.8"/>
                    <measurement group_id="O3" value="93.0" lower_limit="87.1" upper_limit="96.7"/>
                    <measurement group_id="O4" value="94.2" lower_limit="88.8" upper_limit="97.4"/>
                    <measurement group_id="O5" value="96.6" lower_limit="92.2" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="93.9" upper_limit="99.6"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="97.7" lower_limit="93.3" upper_limit="99.5"/>
                    <measurement group_id="O4" value="97.1" lower_limit="92.7" upper_limit="99.2"/>
                    <measurement group_id="O5" value="98.0" lower_limit="94.2" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.2" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.1" lower_limit="92.7" upper_limit="99.2"/>
                    <measurement group_id="O5" value="98.6" lower_limit="95.2" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="127"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" lower_limit="85.3" upper_limit="95.4"/>
                    <measurement group_id="O2" value="94.3" lower_limit="89.1" upper_limit="97.5"/>
                    <measurement group_id="O3" value="96.1" lower_limit="91.1" upper_limit="98.7"/>
                    <measurement group_id="O4" value="95.7" lower_limit="90.8" upper_limit="98.4"/>
                    <measurement group_id="O5" value="95.2" lower_limit="90.4" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="97.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100" lower_limit="97.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="92.0" upper_limit="98.9"/>
                    <measurement group_id="O2" value="96.5" lower_limit="92.0" upper_limit="98.8"/>
                    <measurement group_id="O3" value="96.1" lower_limit="91.1" upper_limit="98.7"/>
                    <measurement group_id="O4" value="95.7" lower_limit="90.8" upper_limit="98.4"/>
                    <measurement group_id="O5" value="98.6" lower_limit="95.2" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="95.0" upper_limit="99.8"/>
                    <measurement group_id="O2" value="98.6" lower_limit="95.0" upper_limit="99.8"/>
                    <measurement group_id="O3" value="96.9" lower_limit="92.2" upper_limit="99.1"/>
                    <measurement group_id="O4" value="100" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98.6" lower_limit="95.2" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="91.0" upper_limit="98.4"/>
                    <measurement group_id="O2" value="100" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.2" lower_limit="95.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.8" lower_limit="93.8" upper_limit="99.5"/>
                    <measurement group_id="O5" value="98.0" lower_limit="94.2" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.4" lower_limit="94.5" upper_limit="99.8"/>
                    <measurement group_id="O4" value="97.1" lower_limit="92.7" upper_limit="99.2"/>
                    <measurement group_id="O5" value="97.3" lower_limit="93.2" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.2" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100" lower_limit="97.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="135"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="85.5" upper_limit="95.5"/>
                    <measurement group_id="O2" value="97.9" lower_limit="93.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="90.6" lower_limit="84.2" upper_limit="95.1"/>
                    <measurement group_id="O4" value="92.6" lower_limit="86.8" upper_limit="96.4"/>
                    <measurement group_id="O5" value="94.6" lower_limit="89.6" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0.8" upper_limit="7.3"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.2" upper_limit="5.1"/>
                    <measurement group_id="O3" value="93.8" lower_limit="88.1" upper_limit="97.3"/>
                    <measurement group_id="O4" value="99.3" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98.6" lower_limit="95.2" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="127"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="148"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.4" upper_limit="6.1"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.4" upper_limit="6.2"/>
                    <measurement group_id="O3" value="39.4" lower_limit="30.8" upper_limit="48.4"/>
                    <measurement group_id="O4" value="75.9" lower_limit="67.9" upper_limit="82.8"/>
                    <measurement group_id="O5" value="93.2" lower_limit="87.9" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Group 5 Versus Group 1: GMC of Anti-PnP IgG For 13 Shared Serotypes Contained in V114 and Prevnar 13™ at 30 Days Post Vaccination 4</title>
        <description>The GMC of anti-PnP serotype-specific IgG for 13 shared serotypes contained in V114 and Prevnar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) was assessed using a PnECL assay. Per protocol, GMC of 13 IgG serotypes was analysed by vaccine dosing schedules (Groups 1, 5). Per protocol, 13 IgG serotypes in Group 5 (experimental arm) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4 as a pre-specified secondary outcome analysis; 13 IgG serotypes in Groups 2, 3, 4 (experimental arms) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4, as a separate protocol-specified primary outcome analysis and reported earlier in the record.</description>
        <time_frame>30 Days after Vaccination 4 (Months 11-14)</time_frame>
        <population>All randomized participants who were compliant with the protocol, got scheduled dosing of V114 or Prevnar 13™, had IgG GMC data available for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F or 23F in Groups 5 or 1 at 30 Days post Vaccination 4. 13 IgG serotypes in Group 5 were compared to Group 1 as a protocol-specified secondary outcome analysis; 13 IgG serotypes in Groups 2, 3, 4 were compared to Group 1 as a separate protocol-specified primary outcome analysis and reported earlier.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
            <description>Participants received a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Prevnar 13™-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: V114-V114-V114-V114</title>
            <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
          </group>
        </group_list>
        <measure>
          <title>Group 5 Versus Group 1: GMC of Anti-PnP IgG For 13 Shared Serotypes Contained in V114 and Prevnar 13™ at 30 Days Post Vaccination 4</title>
          <description>The GMC of anti-PnP serotype-specific IgG for 13 shared serotypes contained in V114 and Prevnar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) was assessed using a PnECL assay. Per protocol, GMC of 13 IgG serotypes was analysed by vaccine dosing schedules (Groups 1, 5). Per protocol, 13 IgG serotypes in Group 5 (experimental arm) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4 as a pre-specified secondary outcome analysis; 13 IgG serotypes in Groups 2, 3, 4 (experimental arms) were compared to Group 1 (comparator arm) at 30 days post Vaccination 4, as a separate protocol-specified primary outcome analysis and reported earlier in the record.</description>
          <population>All randomized participants who were compliant with the protocol, got scheduled dosing of V114 or Prevnar 13™, had IgG GMC data available for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F or 23F in Groups 5 or 1 at 30 Days post Vaccination 4. 13 IgG serotypes in Group 5 were compared to Group 1 as a protocol-specified secondary outcome analysis; 13 IgG serotypes in Groups 2, 3, 4 were compared to Group 1 as a separate protocol-specified primary outcome analysis and reported earlier.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.78" upper_limit="2.30"/>
                    <measurement group_id="O5" value="1.46" lower_limit="1.30" upper_limit="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.64" upper_limit="0.82"/>
                    <measurement group_id="O5" value="0.89" lower_limit="0.79" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.30" upper_limit="1.76"/>
                    <measurement group_id="O5" value="1.35" lower_limit="1.17" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" lower_limit="3.18" upper_limit="4.20"/>
                    <measurement group_id="O5" value="2.90" lower_limit="2.50" upper_limit="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" lower_limit="5.56" upper_limit="7.42"/>
                    <measurement group_id="O5" value="4.43" lower_limit="3.86" upper_limit="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" lower_limit="5.36" upper_limit="7.07"/>
                    <measurement group_id="O5" value="5.83" lower_limit="5.09" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" lower_limit="4.43" upper_limit="5.88"/>
                    <measurement group_id="O5" value="3.43" lower_limit="3.02" upper_limit="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="2.56" upper_limit="3.34"/>
                    <measurement group_id="O5" value="2.89" lower_limit="2.56" upper_limit="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" lower_limit="6.55" upper_limit="8.86"/>
                    <measurement group_id="O5" value="6.57" lower_limit="5.73" upper_limit="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" lower_limit="2.21" upper_limit="2.99"/>
                    <measurement group_id="O5" value="2.65" lower_limit="2.34" upper_limit="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" lower_limit="5.15" upper_limit="6.80"/>
                    <measurement group_id="O5" value="4.66" lower_limit="4.15" upper_limit="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" lower_limit="4.22" upper_limit="5.42"/>
                    <measurement group_id="O5" value="4.10" lower_limit="3.66" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" lower_limit="2.42" upper_limit="3.44"/>
                    <measurement group_id="O5" value="2.11" lower_limit="1.81" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 1 (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 3 (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 4 (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 5 (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 6A (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 6B (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 7F (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 9V (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 14 (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 18C (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 19A (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 19F (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio: Serotype 23F (Group 5 vs 1)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>GMC ratio and CI are estimated from a serotype-specific ANCOVA model utilizing the natural log-transformed antibody concentration as the response and vaccination group and stratification factor as covariates.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious AEs (NSAEs): Up to ~14 days after each vaccination; SAEs and all-cause mortality: Up to ~6 months after Vaccination 4 (up to ~19 months)</time_frame>
      <desc>All-cause mortality was analyzed in all randomized participants; SAEs and NSAEs were analyzed in all randomized participants who received at least 1 dose of study vaccination V114 or Prevnar 13™.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™</title>
          <description>Participants received a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Prevnar 13™-Prevnar 13™-V114-V114</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="E4">
          <title>Group 4: Prevnar 13™-V114-V114-V114</title>
          <description>Participants received a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
        <group group_id="E5">
          <title>Group 5: V114-V114-V114-V114</title>
          <description>Participants received a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants concomitantly received other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="179"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenoviral upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Mycoplasma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Foreign body ingestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hair follicle tumour benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="160" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="163" subjects_at_risk="179"/>
                <counts group_id="E5" subjects_affected="160" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="179"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="137" subjects_affected="85" subjects_at_risk="179"/>
                <counts group_id="E2" events="108" subjects_affected="68" subjects_at_risk="181"/>
                <counts group_id="E3" events="109" subjects_affected="69" subjects_at_risk="178"/>
                <counts group_id="E4" events="130" subjects_affected="77" subjects_at_risk="179"/>
                <counts group_id="E5" events="142" subjects_affected="79" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="106" subjects_affected="62" subjects_at_risk="179"/>
                <counts group_id="E2" events="83" subjects_affected="47" subjects_at_risk="181"/>
                <counts group_id="E3" events="84" subjects_affected="50" subjects_at_risk="178"/>
                <counts group_id="E4" events="75" subjects_affected="45" subjects_at_risk="179"/>
                <counts group_id="E5" events="86" subjects_affected="47" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="158" subjects_affected="79" subjects_at_risk="179"/>
                <counts group_id="E2" events="140" subjects_affected="79" subjects_at_risk="181"/>
                <counts group_id="E3" events="165" subjects_affected="82" subjects_at_risk="178"/>
                <counts group_id="E4" events="156" subjects_affected="78" subjects_at_risk="179"/>
                <counts group_id="E5" events="170" subjects_affected="85" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="58" subjects_affected="41" subjects_at_risk="179"/>
                <counts group_id="E2" events="55" subjects_affected="34" subjects_at_risk="181"/>
                <counts group_id="E3" events="63" subjects_affected="44" subjects_at_risk="178"/>
                <counts group_id="E4" events="59" subjects_affected="37" subjects_at_risk="179"/>
                <counts group_id="E5" events="71" subjects_affected="41" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="83" subjects_affected="53" subjects_at_risk="179"/>
                <counts group_id="E2" events="94" subjects_affected="66" subjects_at_risk="181"/>
                <counts group_id="E3" events="77" subjects_affected="52" subjects_at_risk="178"/>
                <counts group_id="E4" events="78" subjects_affected="49" subjects_at_risk="179"/>
                <counts group_id="E5" events="68" subjects_affected="49" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="179"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="150" subjects_affected="64" subjects_at_risk="179"/>
                <counts group_id="E2" events="95" subjects_affected="58" subjects_at_risk="181"/>
                <counts group_id="E3" events="77" subjects_affected="48" subjects_at_risk="178"/>
                <counts group_id="E4" events="90" subjects_affected="63" subjects_at_risk="179"/>
                <counts group_id="E5" events="121" subjects_affected="62" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="285" subjects_affected="102" subjects_at_risk="179"/>
                <counts group_id="E2" events="241" subjects_affected="101" subjects_at_risk="181"/>
                <counts group_id="E3" events="207" subjects_affected="101" subjects_at_risk="178"/>
                <counts group_id="E4" events="248" subjects_affected="102" subjects_at_risk="179"/>
                <counts group_id="E5" events="237" subjects_affected="108" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="430" subjects_affected="121" subjects_at_risk="179"/>
                <counts group_id="E2" events="362" subjects_affected="110" subjects_at_risk="181"/>
                <counts group_id="E3" events="378" subjects_affected="112" subjects_at_risk="178"/>
                <counts group_id="E4" events="376" subjects_affected="122" subjects_at_risk="179"/>
                <counts group_id="E5" events="434" subjects_affected="126" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="179"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E4" events="20" subjects_affected="18" subjects_at_risk="179"/>
                <counts group_id="E5" events="17" subjects_affected="17" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="179"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="181"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E5" events="15" subjects_affected="14" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="179"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E4" events="20" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E5" events="20" subjects_affected="12" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

